公司資料
Janux 股價、新聞與催化劑
- 股票代碼:
- JANX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
18.60 USD (+6.96%)
收盤價
最後更新: 2026年8月24日
840M USD
市值
股價為何變動
As of Aug 24, 2026, JANX closed up 6.96% at $18.60. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
Janux Therapeutics is a precision-oncology company developing conditional T-cell engager therapies. Its platform aims to improve tumor targeting while limiting off-tumor toxicity.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, Janux sits in specialty oncology biotechnology.
商業模式特徵
The company depends on clinical data, platform validation, and the possibility of creating a differentiated immuno-oncology franchise.
生技產業定位
Janux is a platform oncology name with meaningful upside if its conditional-engager science continues to validate.
未來催化劑
- Janux's catalysts are PSMA and EGFR T-cell engagers, especially JANX007 and the next clinical updates. The company remains highly event-driven.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。